MyWay Genetics is continuously studying and developing new ways in the field of DNA technologies, to implement its core of research and development of innovative solutions for the healthcare sector. This is aligned to our view based on Personalized Medicine.

Personalized medicine refers to a new health care approach, based on individual genetic mark-up, not just disease related but on every aspect of personal health (e.g. individual drugs assimilation patterns, allergies, inherited predispositions).

We are the hub that can completely connect the most advanced results of the omic research with the market: this is the gate for a new dimension of a personal health care system and the access key is DNA.

Networking is the key to rapidly transforming potential solutions into concrete ones.

If you are a professional, a biotech / pharma / healthcare company, a research center or hospital and you are interested in cooperating with us, please contact us.

Project 1

An innovative solution for monitoring graft rejection after transplantation. Every year 100,000 patients undergo organ transplantation all over the world as the only definitive treatment for end-stage organ failure. Independently on the organ transplanted, graft rejection is a major open problem for these patients, occurring when the graft is recognized as foreign, attacked and rejected by the recipient's immune system, causing cellular damage and graft failure. Postoperative care consists of a painful surveillance that lasts a lifetime, with frequent organ biopsies, necessary to guarantee a survival rate of 15 years.
MWG is developing a new and non invasive tool for monitoring rejection, a marketable solution for reliable, safe and non-invasive monitoring of allograft damage, which will allow the monitoring of transplanted patients’ rejection, since early onset and drastically lower the need of frequent organ biopsies.

Precision and personalized medicine, a dream that comes true?

Favalli V, Serio A, Giuliani LP, Arbustini E.

J Cardiovasc Med (Hagerstown). 2017 Jan;18 Suppl 1: Special Issue on The State of the Art for the Practicing Cardiologist: The 2016 Conoscere E Curare Il Cuore (CCC) Proceedings from the CLI Foundation:e1-e6.

Genetic causes of dilated cardiomyopathy

Favalli V, Serio A, Grasso M, Arbustini E.

Heart. 2016 Dec 15;102(24):2004-2014.

Genetic Screening of Anderson-Fabry Disease in Probands Referred From Multispecialty Clinics

Favalli V, Disabella E, Molinaro M, Tagliani M, Scarabotto A, Serio A, Grasso M, Narula N, Giorgianni C, Caspani C, Concardi M, Agozzino M, Giordano C, Smirnova A, Kodama T, Giuliani L, Antoniazzi E, Borroni RG, Vassallo C, Mangione F, Scelsi L, Ghio S, Pellegrini C, Zedde M, Fancellu L, Sechi G, Ganau A, Piga S, Colucci A, Concolino D, Di Mascio MT, Toni D, Diomedi M, Rapezzi C, Biagini E, Marini M, Rasura M, Melis M, Nucera A, Guidetti D, Mancuso M, Scoditti U, Cassini P, Narula J, Tavazzi L, Arbustini E.

J Am Coll Cardiol. 2016 Sep 6;68(10):1037-50.

Left Ventricular Noncompaction: A Distinct Genetic Cardiomyopathy?

Arbustini E, Favalli V, Narula N, Serio A, Grasso M.

J Am Coll Cardiol. 2016 Aug 30;68(9):949-66.

Endomyocardial Biopsy in acute cardiogenic shock: Diagnosis of pheochromocytoma

Kodama T, Agozzino M, Pellegrini C, Narula N, Pietrabissa A, Concardi M, Caspani C, Ghirotto E, Giordano C, Smirnova A, Favalli V, Arbustini E.

Int J Cardiol. 2016 Jan 1;202:897-9.

The MOGE(S) classification of cardiomyopathy for clinicians

Arbustini E, Narula N, Tavazzi L, Serio A, Grasso M, Favalli V, Bellazzi R, Tajik JA, Bonow RO, Fuster V, Narula J.

J Am Coll Cardiol. 2014 Jul 22;64(3):304-18. doi: 10.1016/j.jacc.2014.05.027. Review. Erratum in: J Am Coll Cardiol. 2014 Sep 16;64(11):1186. Bonow, Robert D [Corrected to Bonow, Robert O].

The pathologic basis of recovery

Narula N, Agozzino M, Gazzoli F, Concardi M, Pagani F, Favalli V, Kodama T, Mazzola A, D’Armini AM, Arbustini E.

Heart Fail Clin. 2014 Jan;10(1 Suppl):S63-74. doi: 10.1016/j.hfc.2013.09.001. Review.